First line combination therapy improves progression-free survival in advanced lung cancerDecember 07, 2017
LUGANO-GENEVA, Dec. 7, 2017 - A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017. (1)
"This is the first phase III trial to report on the combination of chemotherapy, antiangiogenic treatment and immunotherapy as first line treatment for advanced non-squamous NSCLC," said lead author Professor Martin Reck, chief oncology physician, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany. "The trial met its co-primary endpoint of PFS and the preliminary results of the co-primary endpoint of overall survival (OS), although immature, look encouraging."
There is a scientific rationale to support the combinations that have been explored in the trial. Bevacizumab may enhance the ability of atezolizumab to restore anti-cancer immunity by inhibiting vascular endothelial growth factor (VEGF)-related immunosuppression and other mechanisms while chemotherapy may induce immune responses. The chemotherapy used in the trial was carboplatin plus paclitaxel. Atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), while bevacizumab is a biologic antiangiogenic drug.
IMpower150 enrolled 1,202 patients who were randomised to one of three arms: A) chemotherapy plus atezolizumab; B) chemotherapy plus atezolizumab plus bevacizumab; or C) chemotherapy plus bevacizumab.
The PFS survival comparison was made between arms B and C and showed that the combination of atezolizumab, bevacizumab and chemotherapy was superior to bevacizumab and chemotherapy alone with a median PFS of 8.3 versus 6.8 months (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.52, 0.74; P < 0.0001) in the intention-to-treat (ITT) wild type (WT) population, which excluded patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
The corresponding median PFS in the Teff-WT population, which included patients with defined expression of a T-effector gene signature in the tumour tissue, was 11.3 versus 6.8 months (HR 0.51; 95% CI 0.38, 0.68; P < 0.0001). PFS benefit was seen regardless of PD-L1 immunohistochemistry status, including PD-L1-negative pts (TC0/IC0: HR 0.77; 95% CI 0.61, 0.99). (2)
There were no new safety signals with the combination therapy. Due to prespecified testing hierachy, Arm A versus C has not been formally tested yet.
Reck said: "There was a significant and clinically relevant improvement in progression-free survival favouring the addition of atezolizumab to bevacizumab and chemotherapy. The results show that there is a way to improve the efficacy of platinum-based chemotherapy in patients with advanced non-squamous NSCLC. There were no new safety signals or toxicity issues with this combination so it appears to be a feasible approach for this group of patients."
Commenting on treatment for advanced non-squamous NSCLC for ESMO, Professor Solange Peters, Head of Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, said: "Immunotherapy is a standard of care treatment after platinum-based chemotherapy in patients with advanced NSCLC. Frontline immunotherapy alone is beneficial in those with a high PD-L1 expression, who make up less than a third of NSCLC patients. (3) The combination of immunotherapy and platinum-based chemotherapy showed positive response rates in unselected non-squamous patients (without PD-L1 selection) in a hypothesis-generating phase II trial, which led to US Food and Drug Administration (FDA) approval." (4)
"IMpower150 is the first phase III randomised trial to formally evaluate the combination of immunotherapy and chemotherapy versus chemotherapy frontline," she continued. "The backbone therapy includes bevacizumab which might, by targeting VEGF, facilitate the immune response and the trafficking of T cells. Median PFS for the immunotherapy arm in patients without EGFR mutations or ALK rearrangements had a promising hazard ratio of 0.62 and a median PFS improvement of a little less than two months."
Peters said the benefit of immunotherapy is best observed at later time points. "When you look at the 12-month PFS, you double the number of patients who have not progressed from 18% without immunotherapy to 37% when you add the immunotherapy," she said. "This is very, very promising. Doubling PFS at one year is something we have not seen with any targeted therapy in unselected patients to date."
Even more important was that the combination of chemotherapy and immunotherapy was beneficial regardless of expression of PD-L1 or a T-effector gene signature. It was also beneficial in patients with alterations in EGFR and ALK, who usually do not do well with immunotherapy. Peters said: "We know that for immunotherapy monotherapy, we need to highly select patients for PD-L1 expression. This trial shows that by combining chemotherapy and immunotherapy you completely delete any need for patient selection according to a particular biomarker. This strategy has the potential to benefit large numbers of patients with advanced NSCLC without the practical difficulties of biomarker testing."
Peters concluded: "These exciting results pave the way for a new standard of care in advanced non-squamous NSCLC. The initial overall survival data looks encouraging, but we must wait for it to mature. We will also need to understand the impact of this combination in patients who have already received other immunotherapies. In the next year, other trials will report results in frontline treatment-naïve NSCLC patients using the combination of chemotherapy and immunotherapy or the combination of two immunotherapy drugs. The challenge will then be to judge which strategy is the best."
Please make sure to use the official name of the meeting in your reports: ESMO Immuno Oncology Congress 2017
Official hashtag: #ESMOImmuno17
References and notes
1 Abstract LBA1_PR 'Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/? bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)' will be presented by Martin Reck during the Proffered Paper session 'Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment' on Thursday, 7 December, 18:15 to 19:15 (CET) in Room A. Annals of Oncology, Volume 28, 2017 Supplement 11.
2 PD-L1 expression was assessed on both tumour cells (TC) and tumour-infiltrating immune cells (IC); and patients were scored as TC 0,
1, 2, or 3 and IC 0, 1, 2, or 3 with an immunohistochemistry test.
3 Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375:1823-1833.
4 Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497-1508.
This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 17,000 members representing oncology professionals from 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
European Society for Medical Oncology
Related Chemotherapy Articles:
A chemotherapy drug used to treat brain cancer may increase vulnerability to depression by stopping new brain cells from growing, according to a new King's College London study out today in Translational Psychiatry.
A Washington State University researcher has documented epigenetic changes in the sperm of men who underwent chemotherapy in their teens.
A brain-boosting protein plays an important role in how well people respond to chemotherapy, researchers report at the ESMO Asia 2016 Congress in Singapore.
It is known from previous research that the ER-beta estrogen receptor often has a protective effect.
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
Two bacterial species that inhabit the human gut activate immune cells to boost the effectiveness of a commonly prescribed anticancer drug, researchers report Oct.
For the last three years the research team has been working on the development of a so-called biomarker to predict treatment effectiveness.
For the first time, researchers have discovered that some leukemia cells harvest energy resources from normal cells during chemotherapy, helping the cancer cells not only to survive, but actually thrive, after treatment.
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called 'sonoporation' with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed.
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London.
Related Chemotherapy Reading:
The Chemotherapy Survival Guide: Everything You Need to Know to Get Through Treatment
by Judith McKay (Author), Tammy Schacher RN OCN MSN (Author)
When you're facing cancer treatment, it's easy to feel overwhelmed and alone. Between the hospital or clinic environment and the medical terminology used by doctors and health care professionals, you may feel as though you've entered a foreign country.
Written by two experienced oncology nurses, this compassionate and comprehensive guide explains in plain English everything you need to know about your treatment, including what you can expect at each stage of chemotherapy and what you can do to prevent or minimize side effects. Packed with practical suggestions, nutritional advice,... View Details
Chemotherapy and Biotherapy Guidelines and Recommendations for Practice
by Martha Polovich (Author), MiKeala Olsen (Author), Kris Lefebvre (Author)
Order your copy of the fourth edition of the best-selling resource used by more than 101,000 healthcare professionals since 2009 and keep up-to-date on the latest chemotherapy, biotherapy, and targeted agents. This new edition of the Chemotherapy and Biotherapy Guidelines and Recommendations for Practice has been revised and updated to reflect the current procedures and practices in your specialty. You'll find that this latest edition incorporates a number of significant changes. To help you find the content and information that you need quickly and easily, the text has been reorganized and... View Details
Chemo: Secrets to Thriving: From someone who’s been there.
by Roxanne Brown (Author), Barbara Mastej (Contributor), John S. Link M.D. (Contributor)
The thought of chemotherapy can be overwhelming, but getting through it doesn’t have to be. Chemo: Secrets to Thriving helps lighten the load. In chronological order, step-by- step, you learn what might occur, why it happens, what you can do (with your doc’s approval), and who to contact for help. Chemo: Secrets to Thriving will be your friend, companion, and guide, giving you the resources to handle possible side effects and better manage your life during chemotherapy. Once you know the secrets in this book you may find yourself still able to enjoy life—and even thrive—while going... View Details
Physicians' Cancer Chemotherapy Drug Manual 2017
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)
Completely revised and updated for 2017, the Physicians' Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens--both on- and off-label--for the treatment of all the major cancers. View Details
Physicians' Cancer Chemotherapy Drug Manual 2018
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)
Completely revised and updated for 2018, the Physicians' Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens--both on- and off-label--for the treatment of all the major cancers. View Details
Stay Healthy During Chemo: The Five Essential Steps
by Mike Herbert ND (Author), Joseph Dispenza (Contributor)
Chemotherapy works to beat your cancer, but it also takes its own toll on your body and your health. During treatment, it is more important than ever to do what you can to keep yourself strong and healthy. The best way of doing that is to work with your body's innate healing powers.
This book offers a treasure chest of practical guidance for feeling good during chemo and beyond. And it does so through 5 basic steps, supporting you to:
Change your thinking and develop an attitude focused on healing.Detoxify with therapeutic baths to promote healing from the inside out.Eat the best... View Details
Chemotherapy: After Side Effects Chart, Cycle Journal & Medical Appointments Diary for Chemo, Oncology, Cancer Treatment & Recovery
by Anthea Peries (Author)
Chemotherapy: After Side Effects Chart, Cycle Journal & Medical Appointments Diary for Chemo, Oncology, Cancer Treatment & Recovery ABOUT THIS BOOK Chemotherapy treatment is planned by a cancer doctor who will explain the aims of the treatment and possible side effects. Your oncology doctor will ask you to sign a form agreeing to treatment and may talk to you about chemotherapy clinical trials. You may also see an oncology nurse and a pharmacist.Chemotherapy is usually given to patients as several sessions of treatment, with rest periods in between. Chemotherapy and... View Details
Chemotherapy and Radiation For Dummies
by Alan P. Lyss (Author), Humberto Fagundes (Author), Patricia Corrigan (Author)
An informative, compassionate guide for cancer patients and their loved ones
Each year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed advice on how to alleviate and cope with side effects-which range from hair loss to nausea to anemia-and describes how good nutrition, meditation, support groups, and other techniques and... View Details
Chemotherapy and Biotherapy Guidelines and Recommendations for Practice
by Martha Polovich (Editor), Julie M. Whitford (Editor), MiKaela Olsen (Editor)
Edited by Martha Polovich, Julie M. Whitford, and MiKaela Olsen, this new edition has been revised and updated to reflect the current procedures and practices in your specialty. Featured are sections detailing principles of antineoplastic therapy, cancer therapy goals and response, fundamentals of administration, pre-treatment, treatment and post-treatment care, side effects of cancer therapy, immediate complications of cytotoxic therapy, and more. Also included are treatment schedules, including dose category and determination, as well as nursing and chemotherapy flow charts, information on... View Details
From Cocktails to Chemotherapy: A Guide to Navigating Cancer in Your 30's: A Guide to Navigating Cancer in Your 30's
by Meredith J. Goldberg (Author)
In 2010 there were 209,060 reported cases of breast cancer in the United States. 207,090 of them were women. At the age of 32, the author, Meredith Goldberg was one of them. From Cocktails to Chemotherapy follows what happened to the author after her August 2010 diagnosis—almost two years of surgeries, scans, MRIs, biopsies, chemotherapy, radiation, and, finally, navigating what happens when the oncologist gives you the okay to resume your regularly scheduled life. Goldberg’s path followed much the same trajectory as tens of thousands of other women have followed with one exception; she... View Details